MVC Technologies Inc., operating as CB2 Insights (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, is pleased to announce the completion of its non-brokered private placement for gross proceeds of C$5.74M.  The raise was conducted concurrently with the Company’s final steps in its previously announced reverse takeover transaction (see previous releases for transaction details – January 23, 2019 and September 7, 2018).  CB2 is pleased to announce that the private placement was oversubscribed from the original offering of C$5 million.

“In the coming weeks we plan to deploy a portion of the proceeds from the financing to continue our acquisitions of US-based medical cannabis evaluation clinics,” said Prad Sekar, Chief Executive Officer, CB2 Insights.  “With our background as clinical practice management operators, our team has proven our ability to increase the revenues and profitability of acquired clinics while reducing patient churn.  The scale we are building is not simply for a roll-up; we are using the data we gather within our operations to bring real-world evidence to the medical cannabis space and to develop new predictive analytics tools for all industry stakeholders.”


New York-based Merida Capital Partners (“Merida”), a private equity fund targeting fundamental growth drivers underpinning the rapid development of the global cannabis industry led the private placement round with C$3.68M.  Having deployed more than $70 million of capital into the cannabis space, Merida holds a diverse portfolio of investments across the entire cannabis supply chain with a focus on medical cultivation, cultivation infrastructure, data and technology services and pharmaceutical development.  Merida’s 23 investments include public companies KushCo Holdings Inc. (OTC.KSHB), GrowGeneration Corp. (OTC.GRWG) and Freedom Leaf Inc. (OTC.FRLF) and private companies Simplifya, New Frontier Data, Mainstem, and Emerald Scientific.

“CB2 Insights fills a critical gap in the market, bringing highly controlled, clinically-validated Real World Evidence to the cannabis industry,” said Mitch Baruchowitz, Managing Partner, Merida Capital Partners.  “We are pleased to add CB2 to our portfolio as we continue to support game-changing tools that engage the medical community while giving doctors and the medical community at large the data they need to confidently recommend cannabis-based medicines.”

Mr. Sekar continued, “Merida’s deep understanding of the cannabis industry, both core and ancillary, makes them an ideal strategic partner for our company moving forward. Attracting a lead order from such a strong presence in the market provides further validation of our vision and our ability to execute on that vision as we enter this pivotal chapter in CB2 Insights’ history.”

Proceeds from the Private Placement will be used to accelerate an aggressive clinical M&A and consolidation strategy which CB2 Insights will execute over the course of the current and next fiscal year.

Source: cb2insights.com

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less